Trials / Completed
CompletedNCT06130345
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran Vaccines in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,196,685 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SPIKEVAX | Intramuscular injection |
Timeline
- Start date
- 2023-04-14
- Primary completion
- 2024-02-29
- Completion
- 2024-08-31
- First posted
- 2023-11-14
- Last updated
- 2024-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06130345. Inclusion in this directory is not an endorsement.